Dr. Suzanne Novak, MD, PHD Anesthesiology - Pain Medicine Medicare: Not Enrolled in Medicare Practice Location: 1600 Flintridge Rd, West Lake Hills, TX 78746 Phone: 512-327-7940 Fax: 512-327-7975 |
Mark William Lucia, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5656 Bee Caves Rd, Suite M-302, West Lake Hills, TX 78746 Phone: 512-697-3502 Fax: 512-371-8788 |
Fanny Andrea Morales, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5656 Bee Caves Rd, Suite M-302, West Lake Hills, TX 78746 Phone: 512-697-3502 Fax: 512-697-3501 |
Dr. Diane Keeler-boysen, Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 4407 Bee Cave Rd, Suite 303, West Lake Hills, TX 78746 Phone: 512-732-0732 Fax: 512-732-0735 |
Dr. Gerald L Farcus, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 309 Westlake Dr, West Lake Hills, TX 78746 Phone: 512-861-5263 |
News Archive
Molecular Health has entered into a commercial license to provide the FDA with use of its SafetyMAP software - formally known as Molecular Analysis of Side Effect information (MASE), to provide a comprehensive and dynamic analytical solution for the detection and molecular analysis of drug-induced adverse events for all marketed drugs and for predicting safety issues of new drug candidates.
A key step in the immune system's response to allergens has been uncovered by researchers at Massachusetts General Hospital (MGH).
Roll Call reports that 22 senators have written the Senate Health, Education, Labor and Pensions Committee asking its leaders to hold hearings on controversial new mammogram guidelines. "The letter came less than a week after the U.S. Preventive Services Task Force recommended looser guidelines for breast cancer screenings. The task force suggested that women wait until they turn 50 to begin screening and then undergo one mammogram every two years instead of every year."
Preliminary clinical trial results from an ongoing Phase 2/3 trial led by Laurent M. Humeau of Inovio Pharmaceuticals suggest the two-dose INO-4800 vaccine is safe for use in adults of varying ages. The results expand on phase 1 trial results that found the vaccine was safe and tolerable in 38 participants.
› Verified 9 days ago